Project Grant RF1AG102732
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $1.561 million on April 15, 2026, under the Aging Research program (CFDA 93.866) to investigate immune aging phenotypes in adult survivors of childhood hematologic malignancies and their association with chronic health conditions including congestive heart failure, coronary artery disease, and frailty. The research applies high-dimensional immunological approaches to characterize distinct aging-associated immune cell...
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $1,571,734 on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate clonal hematopoiesis of indeterminate potential in aging and exceptional longevity in older women. The recipient will conduct epidemiological and mechanistic research on CHIP, an age-related blood cell mutation phenomenon, using approximately 10,000 older women from the Women's Health Initiative cohort, including roughly 7,000 with...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $552,154 on February 1, 2026, under the Aging Research program (CFDA 93.866) to characterize hormone therapy use patterns in women with premature or early menopause, identify patient and physician factors associated with therapy initiation and continuation, and develop a dynamic risk prediction model to identify women at high risk for underuse. The project addresses an evidence gap: up to 3.1...
- Project Grant Award Summary Fred Hutchinson Cancer Center received a $2.59 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 15, 2025, with a completion date of August 31, 2029. This research project investigates adipocyte-derived lipid and mitochondrial signals and their mechanisms in neuroprotection and brain senescence. The research deliverables include scientific findings on how adipocyte-derived lipoproteins...
- The National Institute on Aging awarded the University of Rochester $635,825 under the Aging Research program (CFDA 93.866) on September 15, 2026, to evaluate the effects of a geriatric assessment oncology care model in older adults with advanced cancer by leveraging data linkages. The research links data from two major trials evaluating geriatric assessment in oncology care (NCT02107443, NCT02054741) with Centers for Medicare and Medicaid Services utilization and cost data to assess...
- The National Institute on Aging awarded Harvard Pilgrim Health Care, Inc. $706,310 on May 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal study examining the interplay among reproductive, molecular, and chronological age in relation to aging-related conditions in women. The study leverages existing high-quality data and biosamples from a well-phenotyped population of over 850 women followed from recruitment in early pregnancy in 1999–2002 for over two decades....
- The National Institute on Aging awarded the University of Washington $651,175 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal follow-up study examining the relationship between female pubertal timing and biological aging. The research recruits female participants from the National Institute of Child Health and Human Development Study of Early Child Care and Youth Development (SECCYD), a landmark birth cohort. The study seeks to enroll approximately...
- The National Institute on Aging awarded New York University School of Medicine $3,557,115 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the neurobiological mechanisms linking menopause and cognitive decline in women. The recipient will conduct a longitudinal study mapping neurobiological changes during the menopause transition in a cohort of 120 pre- and perimenopausal women aged 40–48 using state-of-the-art neuroimaging, plasma proteomics, and clinical...
- The National Institute on Aging awarded the Institute For Systems Biology $1.345 million on July 1, 2026, under the Aging Research program (CFDA 93.866) to unravel the sex-frailty paradox and identify sex-specific determinants of frailty. The project runs through June 30, 2031, and is performed in Seattle, Washington. The research pursues three integrated aims: benchmarking the performance and potential sex bias of commonly used frailty assessment tools across multiple large-scale global human...
- The National Institute on Aging awarded Dana-Farber Cancer Institute, Inc. $1,526,573 on July 15, 2026, under the Aging Research program (CFDA 93.866) to conduct research on rejuvenation of aged hematopoietic stem cells and bone marrow niche function via mitochondrial engineering. The research addresses how aging impairs hematopoietic stem cell (HSC) transplantation success by driving mitochondrial dysfunction in donor cells. The work investigates mitochondrial transfer between HSCs and...
The National Institute on Aging awarded Fred Hutchinson Cancer Center $3.35 million on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop personalized guidance for menopausal hormone therapy decision-making. The project will create risk scores combining clinical, demographic, and genetic factors to provide individualized estimates of outcome risk with and without menopausal hormone therapy, addressing seven key MHT-associated outcomes: breast cancer, colorectal cancer, stroke, type 2 diabetes, venous thromboembolism, coronary heart disease, and fracture. The recipient will develop both clinical (non-genetic) and comprehensive (genetic-inclusive) scores to maximize accessibility and usability. In parallel, the project will identify requirements for an MHT risk communication and decision support tool and co-design a prototype in partnership with women and healthcare providers to accelerate clinical translation. Generalizability of the risk scores will be tested by applying models developed using UK Biobank data to the Kaiser Permanente Research Bank. Performance occurs in Seattle, Washington. The project period extends through June 30, 2030. The Aging Research program supports biomedical, social, and behavioral research directed toward understanding the aging process and diseases affecting older populations, with emphasis on Alzheimer's disease and related dementias.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.4m | 8/24/26 |